Vivos (RDGL) Cash from Operations Growth (1y) (2011 - 2025)
Vivos (RDGL) Cash from Operations Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.52 Bn | 176.22 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 128.83 Bn | 125.95 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 108.61 Bn | 99.39 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 68.35 Bn | 66.90 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 48.53 Bn | 44.86 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.42 Bn | 27.30 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 26.92 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 25.49 Bn | 22.36 Bn | 2.07 Bn | 122.43% |
| 10 | Vivos | 26.71 Mn | 25.15 Mn | -3,105.00 | -14.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14.58% |
| Sep 30, 2025 | 9.44% |
| Jun 30, 2025 | -70.09% |
| Mar 31, 2025 | -29.52% |
| Dec 31, 2024 | -1.68% |
| Sep 30, 2024 | -128.12% |
| Jun 30, 2024 | -13.07% |
| Mar 31, 2024 | -19.70% |
| Dec 31, 2023 | -64.43% |
| Sep 30, 2023 | 21.57% |
| Jun 30, 2023 | -83.70% |
| Mar 31, 2023 | 23.59% |
| Dec 31, 2022 | -19.62% |
| Sep 30, 2022 | -58.90% |
| Jun 30, 2022 | 50.71% |
| Mar 31, 2022 | -89.22% |
| Dec 31, 2021 | 35.59% |
| Sep 30, 2021 | 3.18% |
| Jun 30, 2021 | -45.23% |
| Mar 31, 2021 | -132.78% |